<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2022000100006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Seguridad del tratamiento con surfactante pulmonar en el síndrome de dificultad respiratoria aguda en niños]]></article-title>
<article-title xml:lang="en"><![CDATA[Safety of pulmonary surfactant therapy in acute respiratory distress syndrome in children]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Moya]]></surname>
<given-names><![CDATA[Valentín Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Yinet Barrese]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piña]]></surname>
<given-names><![CDATA[Rolando Uranga]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Lianet Díaz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[Leonor Verdecia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Casañas]]></surname>
<given-names><![CDATA[Elaine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Docente &#8220;Martin Chan Puga&#8221; Departamento de Pediatría ]]></institution>
<addr-line><![CDATA[Camagüey ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Nacional Coordinador de Ensayos Clínicos  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Nacional de Sanidad Agropecuaria  ]]></institution>
<addr-line><![CDATA[Mayabeque ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Pediátrico Docente &#8220;Juan Manuel Márquez&#8221;  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2022000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2022000100006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2022000100006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: Los surfactantes pulmonares junto a otras medidas terapéuticas constituyen un tratamiento de elección en diversas afecciones respiratorias.  Objetivo:  Demostrar la seguridad del tratamiento con Surfacen® en el síndrome de dificultad respiratoria aguda en niños.  Materiales y Métodos: Ensayo clínico fase III multicéntrico, abierto, controlado y aleatorizado con dos grupos de tratamiento. El Grupo A recibió tratamiento convencional de oxigenación y ventilación mecánica combinado con Surfacen® en dosis de 100 mg cada ocho horas durante tres días. El Grupo B recibió tratamiento convencional. Se incluyeron niños entre los 28 días de nacido hasta 18 años de edad, de cualquier sexo, con diagnóstico de síndrome de dificultad respiratoria aguda. Se identificó y cuantificó la aparición de eventos adversos, intensidad, actitud seguida ante su aparición, resultado, relación de causalidad y mortalidad al día 28.  Resultados: Se incluyeron 42 niños: 20 en el grupo A y 22 en el grupo B. En el grupo A se reportaron 23 eventos adversos en nueve pacientes y en el grupo B, 97 eventos adversos en 18 pacientes. La hipertensión arterial fue el evento adverso más frecuente. En el grupo A, 73,9% de los eventos adversos se manifestaron con intensidad severa, 86,9 % se mantuvo sin cambios frente al medicamento, 73,9 % tuvo causalidad remota respecto al surfactante. La mortalidad al día 28 fue de 41,5 %; en el grupo A, 20 % y en el grupo B, 62%.  Conclusiones:  Surfacen® fue bien tolerado y seguro al notificarse un número reducido de eventos adversos relacionados con su administración.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Pulmonary surfactants, together with other therapeutic measures, constitute a treatment of choice for various respiratory conditions.  Objective: To demonstrate the safety of the treatment with Surfacen® in acute respiratory distress syndrome in children.  Material and Methods:  A multicenter, open, controlled, randomized Phase III clinical trial with two treatment groups. Group A received conventional oxygen therapy and mechanical ventilation combined with Surfacen® at a dosage of 100 mg every eight hours for three days. Group B received conventional treatment. Children 28 days of life to 18 years of age, of either sex, with the diagnosis of acute respiratory distress syndrome were included. The occurrence of adverse events, intensity, attitude followed after the appearance, outcome, and relationship between causality and mortality at day 28 were identified and quantified.  Results:  A total of 42 children were included: twenty children in group A and twenty-two ones in group B. In group A, 23 adverse events were reported in nine patients, while 97 adverse events were reported in 18 patients from group B. Hypertension was the most frequent adverse event. In group A, 73.9 % of adverse events of severe intensity were reported, 86.9 % remained unchanged after the administration of the drug, and 73.9 % had a remote causality with respect to the surfactant. Mortality at day 28 was 41.5 %; 20 % in group A, and 62 % in group B.  Conclusions:  Surfacen® was safe and well tolerated since a small number of adverse events related to its administration were reported.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de dificultad respiratoria aguda]]></kwd>
<kwd lng="es"><![CDATA[niños]]></kwd>
<kwd lng="es"><![CDATA[surfactante pulmonar]]></kwd>
<kwd lng="es"><![CDATA[eventos adversos]]></kwd>
<kwd lng="en"><![CDATA[Acute respiratory distress syndrome]]></kwd>
<kwd lng="en"><![CDATA[children]]></kwd>
<kwd lng="en"><![CDATA[lung surfactant]]></kwd>
<kwd lng="en"><![CDATA[adverse events]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro Pastrana]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacovigilancia, tecnovigilancia y hemovigilancia: tareas obligatorias durante la pandemia. Entorno Especial 2020 UDLAP]]></source>
<year>2020</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de las Américas Puebla]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Moya]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Barrese]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Casañas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de dificultad respiratoria aguda en niños]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2018</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>126-35</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Durán]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de Surfacen en recién nacidos con dificultad respiratoria]]></article-title>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>2015</year>
<volume>87</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>295-307</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrese Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Sánchez]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Albuerne]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Uranga Piña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Casañas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Limia]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surfactante pulmonar exógeno en adultos con síndrome de dificultad respiratoria aguda]]></article-title>
<source><![CDATA[Neumol Cir Torax]]></source>
<year>2015</year>
<volume>74</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>172-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez Moya]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Machado Lubián]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Barrese Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Albuerne]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Uranga Piña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Hidalgo]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuban Exogenous Pulmonary Surfactant in Treatment of Pediatric Acute Respiratory Distress Syndrome]]></article-title>
<source><![CDATA[MEDICC]]></source>
<year>2017</year>
<volume>19</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>24-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrese Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Sánchez]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Albuerne]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Uranga Piña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Casañas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Limia]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad del tratamiento con surfactante pulmonar en el síndrome de dificultad respiratoria aguda en adultos]]></article-title>
<source><![CDATA[Arch Méd Camagüey]]></source>
<year>2015</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morilla Guzmán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Casañas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Albuerne]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Barrese Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Limia]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Uranga Piña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguridad del tratamiento con Surfacen® en recién nacidos pretérminos con síndrome de dificultad respiratoria]]></article-title>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>2019</year>
<volume>91</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrese Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lim Alonso]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Casañas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Uranga Piña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Albuerne]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la seguridad del uso poscomercial del surfactante cubano, SURFACEN®, en el tratamiento del síndrome de dificultad respiratoria aguda del adulto]]></article-title>
<source><![CDATA[Neumol Cir Torax]]></source>
<year>2019</year>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>296-303</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Centro para el Control Estatal de los Medicamentos, Equipos y Dispositivos Médicos</collab>
<source><![CDATA[Regulación No. 45-2007. Requerimientos para la notificación y el reporte de eventos adversos graves e inesperados en los ensayos clínicos]]></source>
<year>2007</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Centro para el Control Estatal de los Medicamentos, Equipos y Dispositivos Médicos</collab>
<source><![CDATA[Ministerio de Salud Pública de Cuba. Directrices sobre Buenas Prácticas Clínicas en Cuba]]></source>
<year>2000</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Asociación Médica Mundial</collab>
<source><![CDATA[Declaración de Helsinki. Principios éticos para las investigaciones médicas en seres humanos]]></source>
<year>2020</year>
<publisher-loc><![CDATA[París ]]></publisher-loc>
<publisher-name><![CDATA[Asociación Médica Mundial]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Organización de las Naciones Unidas para la Educación, la Ciencia y la Cultura</collab>
<source><![CDATA[Declaración Universal sobre Bioética y Derechos humanos]]></source>
<year>2020</year>
<publisher-loc><![CDATA[París ]]></publisher-loc>
<publisher-name><![CDATA[Organización de las Naciones Unidas para la Educación, la Ciencia y la Cultura]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Exp Ther Med]]></source>
<year>2013</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>237-42</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exogenous surfactant: intubated present, nebulized future?]]></article-title>
<source><![CDATA[World J Pediatr]]></source>
<year>2011</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willson]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Markovitz]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Bauman]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[DiCarlo]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Pon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of exogenous surfactant (Calfactant) in pediatric acute lung injury: a randomized controlled trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2005</year>
<volume>293</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>470-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raghavendran]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Willson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Notter]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surfactant Therapy of ALI and ARDS]]></article-title>
<source><![CDATA[Critical Care Clin]]></source>
<year>2011</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>525-59</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheifetz]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pediatric ARDS]]></article-title>
<source><![CDATA[Respiratory Care]]></source>
<year>2017</year>
<volume>62</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>718-31</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Slutsky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Respiratory Distress Syndrome Advances in Diagnosis and Treatment]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2018</year>
<volume>319</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>698-710</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Chess]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Notter]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surfactant for pediatric acute lung injury]]></article-title>
<source><![CDATA[Pediatr Clin North Am]]></source>
<year>2008</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>545-75</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kesecioglu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beale]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stwart]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Findlay]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Rouby]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Holzapfel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exogenus natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome]]></article-title>
<source><![CDATA[Am J Resp Critical Care Med]]></source>
<year>2009</year>
<volume>180</volume>
<page-range>989-94</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willson]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surfactant composition and biophysical properties are important in clinical studies]]></article-title>
<source><![CDATA[Am J Resp Critical Care Med]]></source>
<year>2010</year>
<volume>181</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira da Silva]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Farias]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Balthar]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exogenous surfactant prevents hyperoxiainduced lung injury in adult mice]]></article-title>
<source><![CDATA[Intensive Care Med Exp]]></source>
<year>2019</year>
<volume>7</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Reskallah]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Eltzschig]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Respiratory Distress Syndrome Contemporary Management and Novel Approaches during COVID-19]]></article-title>
<source><![CDATA[Clin Focus Review]]></source>
<year>2021</year>
<volume>134</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>270-82</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernando]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreyro]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Urner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Munshi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of acute respiratory distress syndrome]]></article-title>
<source><![CDATA[Canadian Medical Association J]]></source>
<year>2021</year>
<volume>193</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>E761-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eugene H]]></surname>
<given-names><![CDATA[Shah V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for surfactant replacement therapy in neonates]]></article-title>
<source><![CDATA[Paediatr Child Health]]></source>
<year>2021</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandis]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento del paciente crítico con síndrome de distrés respiratorio agudo]]></article-title>
<source><![CDATA[Revista Sanitaria de Investigación]]></source>
<year>2021</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>42-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marsegliaa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[D'Angeloa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Granese]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Falsaperlac]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reiterd]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Corselloe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of oxidative stress in neonatal respiratory distress syndrome]]></article-title>
<source><![CDATA[Free Radical Biology and Medicine]]></source>
<year>2019</year>
<volume>142</volume>
<page-range>132-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
